Polypills with or without aspirin for primary prevention of cardiovascular disease

Polypills with or without aspirin for primary prevention of cardiovascular disease

Opis bibliograficzny
Główni autorzy:	Mant, J, McManus, R
Format:	Journal article
Język:	English
Wydane:	Elsevier 2021

Podobne zapisy

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
od: Virdee, S, i wsp.
Wydane: (2013)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
od: Jowett, S, i wsp.
Wydane: (2017)

Polypill for cardiovascular disease prevention.
od: Dalton, A
Wydane: (2013)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
od: Sue Jowett, i wsp.
Wydane: (2017-01-01)

The Concept of the Polypill in the Prevention of Cardiovascular Disease
od: Brandon Wiley, i wsp.
Wydane: (2014-04-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
od: J. Masjuan, i wsp.
Wydane: (2021-01-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
od: Omneya A. Kandil, i wsp.
Wydane: (2022-04-01)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
od: Apichard Sukonthasarn, i wsp.
Wydane: (2021-03-01)

Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study.
od: Sheppard, J, i wsp.
Wydane: (2014)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
od: Lopez-Lopez JP, i wsp.
Wydane: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
od: Gunaratne Padma S, i wsp.
Wydane: (2011-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
od: Samaneh Noroozi, i wsp.
Wydane: (2021-04-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
od: Massimo F. Piepoli
Wydane: (2005-06-01)

The polypill: the solution for prevention of coronary heart disease?
od: Hendarto Natadidjaja
Wydane: (2016-02-01)

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.
od: Sheppard, J, i wsp.
Wydane: (2012)

THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
od: Николай Владимирович Абрамов, i wsp.
Wydane: (2024-02-01)

Role of aspirin in primary prevention of cardiovascular disease
od: Patrono, C, i wsp.
Wydane: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
od: VanWormer JJ, i wsp.
Wydane: (2014-12-01)

Aspirin for primary prevention of cardiovascular disease in diabetes
od: Ying Xing, i wsp.
Wydane: (2019-07-01)

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study
od: Ramin Ravangard, i wsp.
Wydane: (2024-07-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
od: Lilian Grigorian-Shamagian, i wsp.
Wydane: (2021-08-01)

Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for primary for cardiovascular disease prevention
od: Sheppard, J, i wsp.
Wydane: (2013)

The use of polypills in cardiovascular disease management: Benefits vs challenges
od: Yamaan Adil, i wsp.
Wydane: (2024-09-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
od: Reza Jahangiri, i wsp.
Wydane: (2022-01-01)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
od: Hennekens, C, i wsp.
Wydane: (1989)

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
od: Gautam Satheesh, i wsp.
Wydane: (2024-07-01)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
od: Yinong Chen, i wsp.
Wydane: (2021-09-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
od: Siddharth Birla, i wsp.
Wydane: (2023-09-01)

Which people should take aspirin for primary prevention of cardiovascular disease?
od: Lozano R, i wsp.
Wydane: (2015-07-01)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
od: Sergio Coccheri
Wydane: (2017-04-01)

Aspirin for prevention of cancer and cardiovascular disease.
od: Rose, P, i wsp.
Wydane: (2011)

Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
od: Gautam Satheesh, i wsp.
Wydane: (2024-08-01)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
od: Eleni Giannopoulou, i wsp.
Wydane: (2024-12-01)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
od: Athena L. Huang, i wsp.
Wydane: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
od: Athena L. Huang, MD, i wsp.
Wydane: (2023-09-01)

Preventing the progression of climate change: one drug or polypill?
od: Hugh Montgomery
Wydane: (2017-03-01)

Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for stroke and cardiovascular disease prevention
od: Sheppard, J, i wsp.
Wydane: (2013)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
od: Price, H, i wsp.
Wydane: (2009)

Polypill holds promise for people with chronic disease
od: Jacqui Wise
Wydane: (2005-12-01)

Aspirin in the primary prevention of vascular disease Reply
od: Baigent, C, i wsp.
Wydane: (2009)